Abstract Body

Background: Changes in intestinal microbiota, through their effects on energy homeostasis and inflammation, could contribute to the development of several pathologies. Preservation of gut microbiote composition arises as a promising tool to prevent the development of different disorders such as obesity. Maraviroc (MVC), a CCR5 antagonist approved for the treatment of HIV-infected patients, have showed neutral or even beneficial effects on liver and adipocyte metabolism, suggesting beneficial actions in overweight/obese HIV-infected patients. However, MVC impacts on gut microbiota have not been analyzed yet. The aim of this study was to investigate the effects of MVC on gut microbiota composition in a mouse model of obesity. Methodology: A total of 32 male C57BL/6 mice were randomly assigned to one of the following groups: a) Control group (chow diet), b) MVC group (chow diet plus 300 mg/L MVC in the drinking water) c) High-fat diet group (HFD) or d) HFD+MVC group. Body weight and food intake was recorded every 2-3 days. All mice were euthanized after 16 weeks of treatment and cecal contents were removed to study gut microbiota composition. We analyzed by real time PCR four orders from the most dominant phyla in gut. Results: As expected, HFD induced a significant increase in body weight gain (p<0.001). MVC showed a tendency to decrease this body weight gain despite the HFD (p=0.06). Mice fed with a HFD showed a significant increase in the expression of Enterobacteriales in comparison with the controls (p<0.001). MVC treatment induced a significant decrease in the mRNA levels of this order in both control and HFD mice (p<0.001). HFD induced a significant decrease in Bacteroidales and Clostridiales mRNA levels (p<0.05 and p<0.001 respectively). MVC decreased the expression of Bacteroidales in the group of animals fed with a control diet (p<0.05) while a tendency to increase the expression of this order was observed in HFD mice (p=0.05). No direct effects were observed on Clostridiales after MVC supplementation, although a slightly decrease was observed in HFD mice. Finally, HFD significantly increased the mRNA levels of Lactobacillales (p<0.05) while no significant effects were observed after MVC supplementation, although a tendency to decrease the expression levels of this order was observed in HFD mice. Conclusions: This is the first study that demonstrates the ability of MVC to modify gut microbiota composition. Whether the changes in gut microbiota induced by MVC are associated with the lower body weight gain observed, is still unknown. Our results suggest that some MVC actions seem to be dependent on diet composition and the metabolic status of animals. If these facts should be taken into account when we design antiretroviral regimens must be further investigated.